Advanced search×

Propranolol and the risk of hospitalized myopathy: Translating chemical genomics findings into population-level hypotheses

Soko Setoguchi, John M Higgins, Helen Mogun, Vamsi K Mootha, and Jerry Avorn

Am Heart J 159(3):6 (2010) PMID 20211305

Background: A recent large-scale, chemical screening study raised the hypothesis that propranolol may increase the risk of myopathy. We tested this hypothesis in a large population to assess whether (1) propranolol use is associated with an increased risk of myopathy and (2) the concurrent use of propranolol with a statin may further increase risk of myopathy. Methods: New users of propranolol and other @b-blockers (BBs) aged >=65 were identified using data from Medicare and drug benefit programs in 2 states (1994-2005). The primary end point studied was hospitalization for myopathy or rhabdomyolysis. We used stratified Cox proportional hazards regression to estimate the multivariate-adjusted effect of propranolol compared to other BBs and controlled for demographic variables, risk factors for myopathy, other comorbidities, and health service use measures. We also assessed whether co-use of propranolol and statin further increases the risk, by including an interaction term for use of propranolol and statins. Results: We identified 9,304 initiators of propranolol and 130,070 initiators of other BBs and found 30 cases of hospitalized myopathy in 15,477 person-years (PYs) of propranolol use and 523 in 343,132 PYs of other BB use. Comparing propranolol with other BB users, the adjusted hazard ratio was 1.45 (95% CI 1.00-2.11) for myopathy and 1.48 (95% CI 0.82-2.67) for rhabdomyolysis. We could not detect interaction between propranolol and statins due to limited power. Similar results were observed when propranolol users were compared to other antihypertensive drug users. Conclusions: Propranolol may be associated with a 45% increased risk of hospitalized myopathy in the elderly. Our study illustrates how results from in vitro chemical screens can be translated into hypotheses about drug toxicity at the population level.

Copyright © 2010 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.ahj.2009.12.008
Version: za2963e q8zaf q8zbc q8zce q8zd4 q8ze9 q8zf0 q8zgb

Similar articles you may find interesting…

  1. A Pharmacoepidemiologic Analysis of the Impact of Calendar Packaging on Adherence to Self-Administered Medications for Long-Term Use
    Barbara K Zedler, Andrew Joyce, ... Spencer E Harpe

    Clin Ther 33(5):17 (2011) PMID 21665043

    We used linear and logistic regression modeling and propensity score matching to assess the impact of CBP on refill adherence, using medication possession ratio (MPR) and proportion of days covered (PDC), and persistence using length of therapy (LOT). Our sample comprised 76,321 new...
  2. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies.
    Alice Wallin and Susanna C Larsson

    Eur J Cancer 47(11):1606-15 (2011) PMID 21354783

    We therefore conducted a meta-analysis to update and expand the previous results. We searched the PubMed and EMBASE databases through 26 January 2011 and reviewed the reference lists of retrieved articles. Prospective cohort studies were included if they reported relative risk (RR) estimates with 95...
  3. Second malignant neoplasms associated with immunosuppressive medications.
    I Penn

    Cancer 37(2 Suppl):1024-32 (1976) PMID 766952

    Previous studies have shown that immunosuppressive therapy permits the growth and spread of inadvertently transplanted malignant cells in man, and, in addition, is associated with a 5 to 6% incidence of de novo cancers in organ homograft recipients who were apparently free of cancer...